Orchard Therapeutics says it will benefit hugely from GlaxoSmithKline PLC's decision to sell its rare disease portfolio to the three-year old UK biotech, and that its gene therapy programs will remain unencumbered by the 19.9% equity stake and board position that GSK will receive in return.
Britain's biggest drug maker said on April 12 that it would transfer its rare disease gene therapy drugs to privately...








